The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system

BackgroundOfatumumab is a humanized monoclonal antibody that targets CD20-positive B cells. It was approved by the FDA in 2020 for the treatment of relapsing multiple sclerosis (RMS) in adult patients, and in 2009 for the treatment of Chronic Lymphocytic Leukemia (CLL). With the escalating clinical...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yue Zhou, Yutong Wu, Xiao Zhao, Lingxu Xu, Mingguang Sun, Zhaoyou Meng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	ofatumumab FAERS MS CLL pharmacovigilance adverse events
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515730/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
by: Yixuan Yang, et al.
Published: (2025-01-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01)

Expanding on Abraxane Safety: Temporal Insights and Future Directions for Adverse Event Analysis [Letter]
by: Yang F, et al.
Published: (2025-02-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis
by: Amy Perrin Ross, et al.
Published: (2025-01-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
by: Alshareef H, et al.
Published: (2025-02-01)

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database
by: Hunong Xiang, et al.
Published: (2025-01-01)

Pharmacovigilance in veterinary profession
by: Fatih Doğan

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
by: Shuai Zhao, et al.
Published: (2025-02-01)

Examining vaccination-related adverse events in frequent neurodegenerative diseases
by: Shabnam Sodagari, et al.
Published: (2025-02-01)

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Lisi Xu, et al.
Published: (2025-01-01)

A Comprehensive 10-Year Nationwide Pharmacovigilance Surveillance on Antibacterial Agents in Korea: Data Mining for Signal Detection of Trends and Seriousness of Adverse Events
by: Seon Hu Mo, et al.
Published: (2025-01-01)

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

Brodalumab: Six-Year US Pharmacovigilance Report
by: Mark G. Lebwohl, et al.
Published: (2024-11-01)

Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China
by: Yiqing Zhu, et al.
Published: (2025-12-01)

Knowledge, Attitude, Practice, and Barriers of Adverse Drug Reaction Reporting Among Healthcare Professionals in Timor‐Leste: A Cross‐Sectional Survey
by: Juanina daCosta, et al.
Published: (2025-01-01)

Impact of discontinuation of cephazolin prophylaxis on the incidence of postoperative adverse events in cataract surgery
by: Kazutaka Uchida, et al.
Published: (2025-01-01)

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
by: Hui Liang, et al.
Published: (2025-01-01)

Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders
by: Zhong-hua Fu, et al.
Published: (2025-01-01)